Evaluating Donors for Risk of Ebola Disease

For FDA information specific to Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps), please refer to Ebola Disease Information for HCT/P Establishments.

October 22, 2026 - FDA Update

FDA's October 22, 2026 Safety and Availability Communication states that, based on the absence of active cases of Ebola disease in Uganda, blood establishments may discontinue assessing donors for residency in or travel to Uganda. The recommendation to assess donors for residency in or travel to the Democratic Republic of the Congo (DRC) remains in effect. Blood establishments should continue to assess donors for residency in or travel to the DRC and defer donors who have resided in or traveled to the DRC for 8 weeks from the date of departure, in accordance with section III.B.2 of FDA's June 2026 Ebola Guidance and 21 CFR 630.10(e)(2).

AABB note: Discontinuing assessment for Uganda is permitted but not required. Blood establishments and their medical directors may adopt more restrictive donor eligibility criteria than FDA recommends.

June 29, 2026 - Initial FDA Notice (Historical information)

FDA issued a safety and availability notice and updated guidance recommending that blood establishments assess donors for residency in or travel to the DRC and Uganda. The Uganda recommendation was later updated on October 22 (see above). More information is available on CDC's web page.

Information on this page is based on the June 2026 FDA Guidance:
"Recommendations for Assessment of Blood Donor Eligibility, Donor Deferral and Blood Product Management in Response to an Ebola Disease Outbreak” (the Ebola Guidance).

Refer to AABB's Ebola Toolkit for Evaluation of Blood Donors updated in November 2026 for instructions on implementation of FDA recommendations.

To revise your DHQ and Donor Education Material refer to these examples: AABB Ebola DHQ and flowcharts, Ebola Donor Education Material.

1) What is required when there is not an Ebola disease outbreak and FDA has not recommended additional donor screening or specified countries for which Ebola disease should be assessed?

FDA's 2026 recommendations state:
"When there are no countries with an Ebola disease outbreak, self-deferral of donors with a history of Ebola disease should provide sufficient protection. We recommend that you update your donor educational materials to instruct donors with a history of Ebola disease to not donate blood or blood components."
You should:

2) How will I know to implement the additional regulations?
  • FDA, in consultation with CDC, will communicate when the recommendations in section III.A.2 and III.B. of the guidance (additional screening measures) should be implemented and specify the countries for which donor residency and travel history should be assessed.
  • AABB will announce in a News Flash and/or other form of broad communication that the additional donor screening measures should be implemented.
3) What should I do when FDA communicates that the recommendations in section III.A.2 and III.B of the guidance (additional screening measures) should be implemented and specifies the countries for which donor residency and travel history should be assessed?

Within 4 weeks of the date of the FDA communication you should implement:

4) How do we handle post donation information (PDI) and other inventory management concerns?
  • Section III.C., page 6 of the guidance, addresses "Product Retrieval, Quarantine, and Notification."
  • The Ebola guidance includes a unique approach to PDI.
  • Refer to recommendation III.C.2, page 6, which states: "We recommend you contact FDA as soon as possible upon learning that you collected blood or blood components from a donor later determined to have Ebola disease."

Please contact regulatory@aabb.org with questions or for additional information.